Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

1. Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-α: a systematic review and meta-analysis.Hepatology international · 2024
   Pooled it
2. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis.Hepatology international · 2020
   Pooled it
3. Weekly HBsAg Decline Dynamics During Combination Therapy with Interferon and Nucleos(t)ide Analogs: A Retrospective Real-World Study.Viruses · 2026
   Article
4. Comparative effectiveness of tenofovir versus entecavir combined with peginterferon Alfa-2b for functional cure in HBeAg-negative chronic hepatitis B: a propensity score-matched analysis.BMC infectious diseases · 2026
   Article
5. Interferon therapy for chronic hepatitis B in children: an immunological perspective.Frontiers in immunology · 2026
   Review
6. Construction and validation of a predictive model for HBsAg loss in chronic hepatitis B patients treated with Peg-IFNα-2b.Frontiers in cellular and infection microbiology · 2026
   Article
7. Hepatitis B cure: Current situation and prospects.World journal of hepatology · 2024
   Review
8. Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients.Infection and drug resistance · 2023
   Article
9. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2023
   Observational
10. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy.Viruses · 2021
    Review
11. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B.World journal of gastroenterology · 2021
    Review
12. Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.International journal of molecular sciences · 2021
    Review
13. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection.Medicine · 2020
    Article
14. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality.Medicine · 2020
    Observational
15. Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission.Medicine · 2020
    Article
16. HBsAg quantification predicts off-treatment response to interferon in chronic hepatitis B patients: a retrospective study of 250 cases.BMC gastroenterology · 2020
    Article
17. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.International journal of medical sciences · 2020
    Article
18. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma.Infectious agents and cancer · 2020
    Article
19. Smoking behavior and smoking index as prognostic indicators for patients with esophageal squamous cell carcinoma who underwent surgery: A large cohort study in Guangzhou, China.Tobacco induced diseases · 2020
    Article
20. Dynamic change of depression and anxiety after chemotherapy among patients with ovarian cancer.Medicine · 2019
    Observational

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as